Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Ambry Genetics and Caris Life Sciences announced a partnership on cancer genetic testing in the US.

Under the terms of the agreement, Caris will offer Ambry’s 67-gene CancerNext-Expanded gene panel to evaluate the hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling. 

Ambry’s panel analyzes 67 genes associated with an increased hereditary risk of cancer, including brain, breast, colon, ovarian, pancreatic, prostate, renal, and uterine cancers. The Aliso Viejo, California-based firm is part of Konica Minolta Precision Medicine. Caris’ testing platform assesses DNA, RNA, and proteins in a patient’s tumor to guide treatment decisions. The firm is based in Irving, Texas. 

Source: https://www.genomeweb.com/sequencing/ambry-genetics-caris-life-sciences-partner-cancer-genetic-testing